We will develop an ultra-high-sensitivity and high-selectivity next-generation MS system (new pretreatment, ionization, mass separation/detection/measurement, and data analysis method) in this project.

 Searching for biomarker candidates for cancer and Alzheimer’s disease in actual clinical samples and healthy control samples is used to evaluate and verify the individual MS technologies developed by the project and to evaluate and verify next-generation MS systems that combine them.

 In addition, it contributes to clinical care by contributing to the development of early diagnostic procedures.